Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

Journal of the Neurological Sciences

Volumn 341, Issue 1-2, 2014, Pages 22-27

  Kaufman, Michael ^a   Pardo, Gabriel ^b   Rossman, Howard ^c   Sweetser, Marianne T ^d   Forrestal, Fiona ^d   Duda, Petra ^d  

^a Carolinas Health Care System   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c Michigan Institute for Neurological Disorders   (United States)

^d BIOGEN   (United States)

Author keywords

Humoral; Immunity; Immunization; Immunoglobulins; Lymphocytes; Multiple sclerosis; Natalizumab; Vaccines

Indexed keywords

IMMUNOGLOBULIN G; KEYHOLE LIMPET HEMOCYANIN; NATALIZUMAB; TETANUS TOXOID; HEMOCYANIN; IMMUNOLOGIC FACTOR; KEYHOLE-LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; ADOLESCENT; CLINICAL TRIAL; DIAGNOSTIC USE; FOLLOW UP; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROCEDURES; TIME; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HEMOCYANIN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TETANUS TOXOID; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84901190544     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.03.035     Document Type: Article

References (28)

1. S.R. Schwid, M.D. Decker, and M. Lopez-Bresnahan Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a Neurology 65 12 Dec 27 2005 1964 1966
2. A. Bar-Or, M.S. Freedman, M. Kremenchutzky, F. Menguy-Vacheron, D. Bauer, and S. Jodl et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis Neurology 81 6 Aug 6 2013 552 558
3. Gilenya (fingolimod) [prescribing information] 2012 Novartis Pharmaceuticals Corporation East Hanover, NJ
4. C. Boulton, K. Meiser, O.J. David, and R. Schmouder Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study J Clin Pharmacol 52 12 Dec 2012 1879 1890
5. M. Mehling, P. Hilbert, S. Fritz, B. Durovic, D. Eichin, and O. Gasser et al. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients Ann Neurol 69 2 2011 408 413
6. Genzyme European commission approves genzyme's multiple sclerosis treatment Lemtrada™ (alemtuzumab) Accessed September 20, 2013
7. C.L. McCarthy, O. Tuohy, D.A. Compston, D.S. Kumararatne, A.J. Coles, and J.L. Jones Immune competence after alemtuzumab treatment of multiple sclerosis Neurology 81 10 Sep 3 2013 872 876
8. M. Vågberg, U. Kumlin, and A. Svenningsson Humoral immune response to influenza vaccine in natalizumab-treated MS patients Neurol Res 34 7 Sep 2012 730 733
9. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 9 Mar 2 2006 899 910
10. W.J. Sandborn, J.F. Colombel, R. Enns, B.G. Feagan, S.B. Hanauer, and I.C. Lawrance et al. Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 18 Nov 3 2005 1912 1925
11. T.A. Yednock, C. Cannon, L.C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 6364 Mar 5 1992 63 66
12. Tysabri (natalizumab) [prescribing information] 2013 Biogen Idec, Inc. Cambridge, MA
13. D.B. Clifford, A. De Luca, D.M. Simpson, G. Arendt, G. Giovannoni, and A. Nath Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 4 Apr 2010 438 446
14. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 9 Mar 2 2006 911 923
15. C. Janeway, K.M. Murphy, P. Travers, and M. Walport Janeway's immunobiology (immunobiology: the immune system) 7th ed. 2007 Garland Science London, UK
16. G. Frisullo, R. Iorio, D. Plantone, A. Marti, V. Nociti, and A.K. Patanella et al. CD4 + T-bet +, CD4 + pSTAT3 + and CD8 + T-bet + T cells accumulate in peripheral blood during NZB treatment Mult Scler 17 5 May 2011 556 566
17. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, and M.A. Libonati et al. A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 1 Jan 2 2003 15 23
18. R. Planas, I. Jelcic, S. Schippling, R. Martin, and M. Sospedra Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis Eur J Immunol 42 3 Mar 2012 790 798
19. N. Putzki, M.K. Baranwal, B. Tettenborn, V. Limmroth, and E. Kreuzfelder Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells Eur Neurol 63 5 2010 311 317
20. N.G. Wehner, C. Gasper, G. Shopp, J. Nelson, K. Draper, and S. Parker et al. Immunotoxicity profile of natalizumab J Immunotoxicol 6 2 Jun 2009 115 129
21. U.H. von Andrian, and T.R. Mempel Homing and cellular traffic in lymph nodes Nat Rev Immunol 3 11 Nov 2003 867 878
22. P.J. Gergen, G.M. McQuillan, M. Kiely, T.M. Ezzati-Rice, R.W. Sutter, and G. Virella A population-based serologic survey of immunity to tetanus in the United States N Engl J Med 332 12 Mar 23 1995 761 766
23. J.R. Harris, and J. Markl Keyhole limpet hemocyanin (KLH): a biomedical review Micron 30 6 Dec 1999 597 623
24. P.L. Amlot, A.E. Hayes, D. Gray, E.C. Gordon-Smith, and J.H. Humphrey Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine Clin Exp Immunol 64 1 Apr 1986 125 135
25. H.H. Birdsall, and R.D. Rossen Characterization of anti-Fab' antibodies in human sera: identification of soluble immune complexes that contain hidden anti-KLH and blocking anti-immunoglobulins following immunization with keyhole limpet haemocyanin Clin Exp Immunol 53 2 Aug 1983 497 504
26. M.J. Welch, S. Fong, J. Vaughan, and D. Carson Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid Clin Exp Immunol 51 2 Feb 1983 299 304
27. D.A. Talan, F.M. Abrahamian, G.J. Moran, W.R. Mower, K. Alagappan, and B.R. Tiffany et al. Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds Ann Emerg Med 43 3 Mar 2004 305 314
28. G.F. Reed, B.D. Meade, and M.C. Steinhoff The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data Pediatrics 96 3 Pt 2 Sep 1 1995 600 603